Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE5.8900
- TODAY'S CHANGE (%)-0.1500 (-2.4834%)
- Bid / Lots5.6800/ 2
- Ask / Lots5.9000/ 5
- Open / Previous Close6.0200 / 6.0400
- Day Range
- 52 Week Range
- Volume863,580
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 96306 | 6 |
| 09:39 ET | 671 | 5.95 |
| 09:43 ET | 3364 | 6.0199 |
| 09:45 ET | 422 | 5.93 |
| 09:48 ET | 2534 | 5.97 |
| 09:50 ET | 1500 | 5.9202 |
| 09:52 ET | 400 | 5.89 |
| 09:54 ET | 200 | 5.94 |
| 09:56 ET | 500 | 5.945 |
| 09:59 ET | 400 | 5.95 |
| 10:01 ET | 100 | 5.96 |
| 10:03 ET | 2357 | 5.93 |
| 10:06 ET | 1200 | 5.91 |
| 10:08 ET | 1039 | 5.9007 |
| 10:12 ET | 5600 | 5.89 |
| 10:14 ET | 1067 | 5.87 |
| 10:15 ET | 340 | 5.86 |
| 10:19 ET | 270 | 5.91 |
| 10:21 ET | 400 | 5.9 |
| 10:28 ET | 300 | 5.9 |
| 10:30 ET | 900 | 5.91 |
| 10:32 ET | 200 | 5.91 |
| 10:33 ET | 100 | 5.9 |
| 10:37 ET | 100 | 5.9 |
| 10:39 ET | 500 | 5.91 |
| 10:48 ET | 506 | 5.89 |
| 10:50 ET | 1095 | 5.88 |
| 10:55 ET | 100 | 5.88 |
| 11:00 ET | 200 | 5.88 |
| 11:02 ET | 3927 | 5.86 |
| 11:04 ET | 477 | 5.8685 |
| 11:06 ET | 100 | 5.86 |
| 11:08 ET | 2128 | 5.89 |
| 11:09 ET | 200 | 5.87 |
| 11:11 ET | 2712 | 5.82 |
| 11:13 ET | 129 | 5.81 |
| 11:15 ET | 400 | 5.83 |
| 11:18 ET | 300 | 5.8 |
| 11:20 ET | 700 | 5.82 |
| 11:22 ET | 300 | 5.84 |
| 11:24 ET | 2313 | 5.841 |
| 11:26 ET | 4935 | 5.82 |
| 11:27 ET | 200 | 5.85 |
| 11:29 ET | 100 | 5.84 |
| 11:31 ET | 1000 | 5.81 |
| 11:33 ET | 16841 | 5.78 |
| 11:36 ET | 17578 | 5.75 |
| 11:38 ET | 7905 | 5.76 |
| 11:40 ET | 567 | 5.785 |
| 11:42 ET | 400 | 5.83 |
| 11:44 ET | 100 | 5.82 |
| 11:45 ET | 100 | 5.83 |
| 11:47 ET | 840 | 5.83 |
| 11:49 ET | 1370 | 5.84 |
| 11:54 ET | 100 | 5.83 |
| 11:56 ET | 800 | 5.839 |
| 11:58 ET | 750 | 5.87 |
| 12:00 ET | 2800 | 5.88 |
| 12:03 ET | 1082 | 5.858 |
| 12:05 ET | 4143 | 5.8709 |
| 12:07 ET | 5042 | 5.8749 |
| 12:14 ET | 1702 | 5.86 |
| 12:16 ET | 210 | 5.86 |
| 12:18 ET | 100 | 5.85 |
| 12:21 ET | 240 | 5.85 |
| 12:23 ET | 100 | 5.84 |
| 12:27 ET | 300 | 5.86 |
| 12:30 ET | 100 | 5.86 |
| 12:36 ET | 1700 | 5.8388 |
| 12:50 ET | 120 | 5.82 |
| 12:52 ET | 15553 | 5.8 |
| 12:54 ET | 30861 | 5.75 |
| 12:56 ET | 2428 | 5.745 |
| 12:57 ET | 483 | 5.74 |
| 01:01 ET | 319 | 5.73 |
| 01:03 ET | 1400 | 5.7 |
| 01:06 ET | 1575 | 5.71 |
| 01:08 ET | 200 | 5.73 |
| 01:10 ET | 974 | 5.7599 |
| 01:12 ET | 1500 | 5.76 |
| 01:14 ET | 400 | 5.77 |
| 01:15 ET | 700 | 5.76 |
| 01:17 ET | 517 | 5.77 |
| 01:19 ET | 300 | 5.77 |
| 01:21 ET | 550 | 5.77 |
| 01:24 ET | 1168 | 5.77 |
| 01:26 ET | 300 | 5.78 |
| 01:28 ET | 400 | 5.77 |
| 01:30 ET | 1973 | 5.79 |
| 01:32 ET | 300 | 5.79 |
| 01:33 ET | 300 | 5.79 |
| 01:35 ET | 26736 | 5.8283 |
| 01:37 ET | 1113 | 5.84 |
| 01:39 ET | 200 | 5.85 |
| 01:42 ET | 400 | 5.83 |
| 01:44 ET | 162 | 5.83 |
| 01:46 ET | 300 | 5.84 |
| 01:48 ET | 400 | 5.84 |
| 01:50 ET | 300 | 5.84 |
| 01:51 ET | 300 | 5.84 |
| 01:53 ET | 1698 | 5.79 |
| 01:55 ET | 200 | 5.8 |
| 01:57 ET | 496 | 5.801 |
| 02:00 ET | 300 | 5.82 |
| 02:02 ET | 300 | 5.82 |
| 02:04 ET | 700 | 5.79 |
| 02:06 ET | 300 | 5.8 |
| 02:08 ET | 300 | 5.8 |
| 02:09 ET | 100 | 5.8 |
| 02:11 ET | 200 | 5.8 |
| 02:13 ET | 656 | 5.79 |
| 02:15 ET | 200 | 5.82 |
| 02:18 ET | 300 | 5.81 |
| 02:20 ET | 300 | 5.82 |
| 02:22 ET | 300 | 5.82 |
| 02:24 ET | 300 | 5.82 |
| 02:26 ET | 600 | 5.815 |
| 02:27 ET | 5788 | 5.82 |
| 02:29 ET | 10092 | 5.8399 |
| 02:31 ET | 200 | 5.82 |
| 02:33 ET | 200 | 5.82 |
| 02:36 ET | 200 | 5.82 |
| 02:38 ET | 1000 | 5.8 |
| 02:40 ET | 1105 | 5.78 |
| 02:42 ET | 300 | 5.79 |
| 02:44 ET | 261 | 5.79 |
| 02:45 ET | 537 | 5.81 |
| 02:47 ET | 300 | 5.82 |
| 02:49 ET | 200 | 5.82 |
| 02:51 ET | 1100 | 5.81 |
| 02:54 ET | 700 | 5.82 |
| 02:56 ET | 200 | 5.84 |
| 02:58 ET | 600 | 5.82 |
| 03:00 ET | 500 | 5.82 |
| 03:02 ET | 600 | 5.83 |
| 03:03 ET | 414 | 5.84 |
| 03:05 ET | 300 | 5.84 |
| 03:07 ET | 500 | 5.84 |
| 03:09 ET | 3000 | 5.86 |
| 03:12 ET | 200 | 5.86 |
| 03:14 ET | 458 | 5.86 |
| 03:16 ET | 2241 | 5.885 |
| 03:18 ET | 800 | 5.88 |
| 03:20 ET | 200 | 5.89 |
| 03:21 ET | 200 | 5.89 |
| 03:23 ET | 289 | 5.9 |
| 03:25 ET | 300 | 5.9 |
| 03:27 ET | 100 | 5.9 |
| 03:30 ET | 100 | 5.9 |
| 03:34 ET | 2000 | 5.92 |
| 03:36 ET | 200 | 5.92 |
| 03:38 ET | 300 | 5.93 |
| 03:39 ET | 1100 | 5.94 |
| 03:41 ET | 1739 | 5.93 |
| 03:43 ET | 600 | 5.92 |
| 03:45 ET | 2228 | 5.91 |
| 03:48 ET | 300 | 5.91 |
| 03:50 ET | 5989 | 5.9 |
| 03:52 ET | 3062 | 5.93 |
| 03:54 ET | 4331 | 5.92 |
| 03:56 ET | 4776 | 5.88 |
| 03:57 ET | 3695 | 5.895 |
| 03:59 ET | 263726 | 5.89 |
Sep 5, 2024
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26(th) Annual Global Investment Conference, from 7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 350.0M | -9.2x | --- |
Lexeo Therapeutics Inc | 356.4M | -3.8x | --- |
Inozyme Pharma Inc | 359.5M | -3.9x | --- |
Jasper Therapeutics Inc | 360.7M | -4.7x | --- |
Korro Bio Inc | 337.8M | -1.2x | --- |
Design Therapeutics Inc | 332.9M | -6.5x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Principal Financial Officer and Principal Accounting Officer
- Michael Alfieri
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $350.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.43 |
EPS | $-0.64 |
Book Value | $2.02 |
P/E Ratio | -9.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
